ArticleBMC infectious diseases2026
Landouzy sepsis in a young adult with multiorgan failure: successful ECMO-assisted management using an individualized antituberculous regimen.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFulminant disseminated tuberculosis (TB) presenting as Landouzy sepsis is rare but carries high mortality. When complicated by acute respiratory distress syndrome (ARDS) and multiorgan failure, evidence for optimal management, including extracorporeal membrane oxygenation (ECMO) and modified antituberculous regimens, remains limited. CASE PRESENTATION: We describe a 23-year-old man with miliary tuberculosis who developed Landouzy sepsis, ARDS, hepatic dysfunction, and refractory hypoxemia requiring veno-venous (VV) and subsequent veno-veno-venous (VVV) ECMO for six weeks. Standard anti-TB treatment for susceptible mycobacteria was withheld due to liver injury most likely related to antituberculous drug toxicity. Despite initial treatment with isoniazid, rifampicin, and ethambutol, rising bilirubin prompted rifampicin discontinuation and transition to an individualized regimen including ethambutol, isoniazid, levofloxacin, bedaquiline, and amikacin. Corticosteroid therapy was started for suspected secondary organizing pneumonia during persistent hypercapnic respiratory failure, followed by clinical improvement. The course was complicated by thrombocytopenia, pneumothorax, arrhythmia, plasma exchange-dependent hyperbilirubinemia, and amikacin-associated sensorineural hearing loss. Microbiological clearance was achieved, organ dysfunction progressively recovered, and first-line therapy was successfully reintroduced after stabilization. The patient was ultimately discharged without oxygen requirement and started a rehabilitation program.
conclusionsThis case highlights that even life-threatening tuberculosis with multiorgan failure can be survivable. Early diagnosis, flexible adaptation of anti-TB therapy, and prolonged ECMO support within multidisciplinary care were key to clinical recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.